

1 **Disease burden and clinical severity of the first pandemic wave of COVID-19 in**
2 **Wuhan, China**

3
4 Juan Yang, PhD ^{1#}, Xinhua Chen, BSc ^{1#}, Xiaowei Deng, MSc ¹, Zhiyuan Chen, BSc ¹,
5 Hui Gong, BSc ¹, Han Yan, BSc ¹, Qianhui Wu, BSc ¹, Huilin Shi, BSc ¹, Shengjie
6 Lai, PhD ^{1,2}, Marco Ajelli, PhD³, Cecile Viboud, PhD⁴, Prof Hongjie Yu, PhD¹

7
8 [#]These authors contributed equally to this work.

9 Corresponding author to Prof. Hongjie Yu, yhj@fudan.edu.cn

10

11 **Affiliations:**

12 1. School of Public Health, Fudan University, Key Laboratory of Public Health
13 Safety, Ministry of Education, Shanghai, China

14 2. WorldPop, Department of Geography and Environment, University of
15 Southampton, University Road, Southampton, SO17 1BJ, UK

16 3. Department of Epidemiology and Biostatistics, Indiana University School of Public
17 Health, Bloomington, IN, USA

18 4. Division of International Epidemiology and Population Studies, Fogarty
19 International Center, National Institutes of Health, Bethesda, MD, USA

20 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

- 21 This study does not necessarily represent the views of the US government or the
22 National Institutes of Health.
23
24 Word count (abstract): 148
25 Word count (main text):3,720
26 Running head: Disease burden and clinical severity of COVID-19 in Wuhan

27 **Abstract**

28 The pandemic of novel coronavirus disease 2019 (COVID-19) began in Wuhan,
29 China, where a first wave of intense community transmission was cut short by
30 interventions. Using multiple data source, we estimated the disease burden and
31 clinical severity of COVID-19 by age in Wuhan from December 1, 2019 to March 31,
32 2020. We adjusted estimates for sensitivity of laboratory assays and accounted for
33 prospective community screenings and healthcare seeking behaviors. Rates of
34 symptomatic cases, medical consultations, hospitalizations and deaths were estimated
35 at 796 (95%CI: 703-977), 489 (472-509), 370 (358-384), and 36.2 (35.0-37.3) per
36 100,000 persons, respectively. The COVID-19 outbreak in Wuhan had higher burden
37 than the 2009 influenza pandemic or seasonal influenza, and that clinical severity was
38 similar to that of the 1918 influenza pandemic. Our comparison puts the COVID-19
39 pandemic into context and could be helpful to guide intervention strategies and
40 preparedness for the potential resurgence of COVID-19.

41 **Introduction**

42 As of 26 July 2020, 188 countries have been affected by the novel coronavirus disease
43 2019 (COVID-19), with 15,745,102 COVID-19 cases and 644,661 deaths reported
44 worldwide¹. COVID-19 has a broad spectrum of severity. The bottom of the severity
45 pyramid includes serological-confirmed infections, of which only a fraction will
46 develop symptoms. A fraction of symptomatic cases may seek medical care, when
47 they can be identified via surveillance systems, require hospitalization and die.
48 Hospitalization is an important metric as it determines the strain exerted by an
49 epidemic on the health care system. Further, deaths are highly relevant to planning
50 pandemic response, as mortality is an outcome that health authorities typically aim to
51 minimize. (Fig.1a)

52
53 Estimates of disease burden and clinical severity of COVID-19 are critical to identify
54 appropriate intervention strategies, plan for healthcare needs, and ensure the
55 sustainability of the health system throughout the duration of the pandemic. However,
56 quantifying these estimates based on surveillance data is challenging due to changes
57 in health seeking behaviors during the pandemic, as well as underdiagnoses. For
58 instance, the detection of a novel pathogen may give a high rate of false negatives.

59
60 Historically, two influenza pandemics had far-reaching influence to humankind
61 worldwide: the 1918 and 2009 influenza pandemics². The 1918 influenza pandemic is

62 typically considered as the worst-case pandemic scenario for pandemic planning. In
63 contrast, the 2009 influenza pandemic is considered mild but provides a benchmark
64 for a pandemic in modern times, as the health systems, supportive care, and
65 populations, are comparable with those of today. Comparing the COVID-19 burden
66 and clinical severity with past influenza pandemics can help public health officials
67 interpret the magnitude of the COVID-19 pandemic and the success of the response
68 efforts. A further comparison between the COVID-19 pandemic and seasonal
69 influenza can be useful to optimize health resource allocations, considering their
70 overlapping circulation periods.

71

72 Wuhan is a particularly well-suited location to assess the health burden of COVID-19.
73 Firstly, Wuhan experienced intense community transmission of severe acute
74 respiratory syndrome coronavirus 2 (SARS-CoV-2); secondly, the first wave has
75 ended, with only seven sporadic cases reported between March 24 and May 18³.
76 Therefore, the first epidemic wave in Wuhan (for the period December 1, 2019-March
77 31, 2020) is an opportunity to comprehensively quantify the disease burden and
78 clinical severity of COVID-19. Here we used multiple data sources to estimate age-
79 specific rates of symptomatic SARS-CoV-2 infections, medically attended cases,
80 hospitalizations, and deaths, accounting for health seeking behaviors and
81 underdiagnoses. We also estimated rates of medically attended influenza-like-illness
82 (ILI) associated with SARS-CoV-2 infections; hospitalizations with severe acute

83 respiratory infection (SARI), and pneumonia hospitalizations associated with SARS-
84 CoV-2 infections by dividing the number of ILI consultations, SARI hospitalizations
85 and pneumonia hospitalizations by the number of symptomatic SARS-CoV-2
86 infections. Moreover, we estimated the clinical severity of COVID-19 including the
87 symptomatic case-fatality risk (sCFR), medically attended case-fatality risk (mCFR),
88 hospitalization-fatality risk (HFR), symptomatic case-hospitalization risk (sCHR), and
89 medically attended case-hospitalization risk (mCHR). The rates of symptomatic cases,
90 medically attended cases, hospitalizations, and deaths with SARS-CoV-2 were
91 calculated by dividing the number of cases at each level of severity by population
92 size. Clinical severity was obtained by dividing the numbers of cases in the
93 corresponding severity pyramid. (Fig.1a) Finally, we compared our estimates with
94 those of the 1918 and 2009 influenza pandemics, and with seasonal influenza.

95

96 **Results**

97 **Reported COVID-19 cases**

98 We obtained the number of laboratory-confirmed COVID-19 cases and clinically-
99 diagnosed cases in Wuhan from published literature and the Hubei Health
100 Commission^{3,4}. Cases were mainly confirmed by real-time reverse transcription
101 polymerase chain reaction (RT-PCR) and included mild, moderate, severe, and critical
102 cases^{5,6,7,8}. Mild cases refer to cases with mild symptoms and no radiographic
103 evidence of pneumonia. Moderate cases refer to cases with fever, respiratory

104 symptoms, and radiographic evidence of pneumonia. Severe cases refer to cases with
105 any breathing problems, finger oxygen saturation, and low PaO₂/FiO₂ (PaO₂ denotes
106 partial pressure of oxygen in arterial blood; FiO₂ denotes fraction of inspired oxygen),
107 etc. Critical cases refer to cases having any respiratory failure, shock, and any other
108 organ failure that requires ICU admission. Clinically-diagnosed cases included
109 suspected cases with pneumonia as indicated by chest radiography, but without
110 virological confirmation of infection⁶. (Supplementary Information File 1) These
111 clinically-diagnosed cases were included in our study, recognizing the value of a
112 clinical definition at the peak of a pandemic and in the context of limited laboratory
113 testing capacity. A total of 50,333 COVID-19 cases were reported in the four-month
114 epidemic in Wuhan. Of them, 32,968 (65.5 %) were laboratory-confirmed cases. As
115 of July 20, 3,869 cases have died, and all others recovered. These cases were recorded
116 from passive surveillance which was launched at the start of the outbreak in late
117 December 2019 in Wuhan⁹, and from active door-to-door and individual-to-individual
118 screenings for fever (Supplementary Information File 2)^{10, 11}.

119

120 **Estimated disease burden of COVID-19**

121 RT-PCR sensitivity for SARS-CoV-2 detection varies based on the interval between
122 symptom onset and laboratory testing, which was highest (97.9%) at an interval of <7
123 days¹². A population-based telephone and online survey conducted in Wuhan found
124 that 35.4% (95%CI 28.4%-43.9%) of patients with acute respiratory infections (i.e.,

125 fever with any symptoms of cough, and/or sore throat) sought medical care during the
126 epidemic of COVID-19¹³. All cases from passive surveillance were considered as
127 medically attended cases. In the baseline analysis, we assumed that a proportion of
128 mild cases, and all moderate-to-critical cases (had radiographic evidence of
129 pneumonia) captured by active screening in the community would eventually seek
130 medical care given that the health system was not overwhelmed. It was assumed that
131 the cases from passive surveillance had the same health seeking behavior as those
132 captured by active screening in the community. Laboratory-confirmed cases
133 (moderate-to-critical) and clinically-diagnosed cases had radiographic evidence of
134 pneumonia, and thus were considered as requiring hospitalization. (Fig.1b)

135
136 After adjusting for sensitivity of RT-PCR testing, and accounting for the probability
137 of seeking medical care and prospective screening in the community, we estimated
138 that a total of 52,300 (95%CI 50,500-54,500) medically-attended cases and 39,600
139 (95%CI 38,300-41,100) hospitalizations were associated with COVID-19. In Wuhan,
140 over the period from December 2019 to March 2020, the rates of symptomatic cases,
141 medical consultations, hospitalizations and deaths for COVID-19 were 796 (95%CI
142 703-977), 489 (95%CI 472-509), 370 (95%CI 358-384) and 36.2 (95%CI 35.0-37.3)
143 per 100,000 individuals respectively. A consistent increasing trend with age was
144 observed across all metrics, with the highest rates occurring in adults aged 60 years
145 and over (Fig.2a, Fig.3a, Fig.4a and Supplementary Information File 3).

146

147 The rate of medical consultation for COVID-19 (mean: 489 per 100,000 individuals)
148 was lower than that of the 2009 influenza pandemic in China and the US (680 and
149 1,030 per 100,000 individuals, respectively). The rate of medical consultation was
150 intermediate between that of the 2012-2013 influenza season in the US (1,070 per
151 100,000 persons) and the 2006-2015 influenza seasons in China (mean: 250 per
152 100,000 individuals per year)^{14, 15}. (Fig.2a-2e and Supplementary Information File 3-
153 4)

154

155 The hospitalization rates of COVID-19 in Wuhan were 3.1-fold higher than that of the
156 2009 influenza pandemic, and 1.8-2.6 times that of seasonal influenza^{16, 17, 18, 19}.

157 Higher hospitalization burden was found among older adults for COVID-19, while the
158 hospital burden was shifted towards children for seasonal influenza in China²⁰ and the
159 2009 influenza pandemic in the US¹⁶. (Fig.3 and Supplementary Information File 3-4)

160 The overall mortality rate of COVID-19 in Wuhan was much higher than that of 2009
161 influenza pandemic and seasonal influenza (36.2 vs. 3.6-6.5 per 100,000 individuals)
162 ^{20, 21, 22}. (Fig.4 and Supplementary Information File 3-4)

163

164 **Estimated clinical severity of COVID-19**

165 The overall sCFR of COVID-19 was 4.54% (95%CI 3.70-5.14%), which is
166 comparable, if not higher, than that of the 1918 influenza pandemic – from the

167 analysis of data from eight US localities, the sCFR was estimated at 1.61% and 1.98%
168 for the first and second wave, respectively^{23, 24}. Such a figure is substantially higher
169 than that of the 2009 influenza pandemic (<0.1% in the US)²⁵. The sCFR of COVID-
170 19 was higher for adults aged ≥ 60 years than for the other age groups (9.09% vs.
171 0.36%-1.97%). (Fig.5a-5c and Supplementary Information File 5) In contrast,
172 younger age groups were the most affected segment of the population during the 1918
173 and 2009 influenza pandemic, while both young and old individuals were the most
174 affected during seasonal influenza epidemics^{14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26}.

175

176 The HFR (9.77%, 95% CI 9.41%-10.10%) and sCHR (46.48%, 95% CI: 39.33%-
177 50.93%) were higher for COVID-19 than for the 2009 influenza pandemic (HFR:
178 2.6% in North America²⁶; sCHR: 1.44% in the US²⁵)(Fig.5e-5h and Supplementary
179 Information File 5).

180

181 **Sensitivity analyses**

182 To assess the robustness of our findings, we conducted four sensitivity analyses: In
183 scenario i) we assumed that moderate cases had the same health seeking behavior as
184 mild cases, i.e., only a proportion of moderate cases sought medical assistance; in
185 scenario ii) we excluded clinically-diagnosed cases; in scenario iii) we used the upper
186 limit of 95%CI of the probability of seeking medical care; and in scenario iv) we used
187 the lower limit of 95%CI of the probability of seeking medical care. Compared to the

188 baseline analysis, the mean rates of symptomatic cases for COVID-19 increased from
189 796 to 935 per 100,000 persons in scenario i) and 960 per 100,000 persons in scenario
190 iv), while rates decreased to 634 per 100,000 persons in scenario ii) and 719 per
191 100,000 persons in scenario iii). The sCFR decreased from 4.54% to 3.87% in
192 scenario i) and 3.77% in scenario iv), while it increased to 5.38% in scenario ii) and
193 5.03% in scenario iii). Similar patterns were observed for the other metrics of interests
194 (Supplementary Information File 3). Overall, the estimated variations did not change
195 our findings, particularly for comparison of COVID-19 with pandemic and seasonal
196 influenza.

197

198 **ILI consultations and SARI/pneumonia hospitalizations**

199 We quantitatively assessed the impact of COVID-19 on the healthcare sector using
200 the local number of ILI consultations and SARI/pneumonia hospitalizations in the
201 absence of COVID-19 as a reference. The rate of medically attended COVID-19 was
202 approximately 1.3 times the baseline ILI consultations among adults of ≥ 60 years of
203 age. The hospitalization rate of COVID-19 was 3-6 fold higher than baseline SARI
204 hospitalizations among adults of ≥ 20 years of age, and 25-132 fold higher than
205 pneumonia hospitalizations as a reference (and Supplementary Information File 6).

206

207 **Discussion**

208 This study uses multiple sources of data to estimate different levels of the COVID-19
209 severity pyramid. We find that the mean rates of symptomatic cases, medical
210 consultations, hospitalizations and deaths were respectively 796, 489, 370, and 36.2
211 per 100,000 persons in Wuhan from December 2019 to March 2020. All burden
212 metrics increased with age, with adults ≥ 60 years of age most affected. Similarly, the
213 highest sCFR and HFR were found in older adults.

214

215 Our study is strengthened by adjustment for several potential biases. First, rates of
216 medical consultations were adjusted by the sensitivity of RT-PCR assays¹².
217 Sensitivity was only 30-40% before January 23 due to delayed detection, which could
218 lead to important underdiagnoses and has not been considered in previous studies.
219 Second, we accounted for the health seeking behaviors among the Wuhan population
220 during the epidemic¹³. The probability of seeking medical treatment conditionally on
221 symptoms of acute respiratory diseases is a critical parameter to estimate the true
222 number of COVID-19 cases in community. Accordingly, our estimates of disease
223 burden may be the most accurate for Wuhan so far.

224

225 Two studies reported on COVID-19 disease burden in the US and Canada by the end
226 of May, at which time local epidemics are still ongoing (Supplementary Information
227 File 7)^{27, 28}. The overall rate of symptomatic cases (796 vs. 404-534 per 100,000
228 persons) in Wuhan was much higher than that in the US and Québec, a severely

229 affected province of Canada. Variation in testing strategies likely contribute to the
230 difference in rate of symptomatic cases, in addition to true difference in epidemic
231 dynamics. Unlike in Wuhan, only individuals with signs or symptoms consistent with
232 COVID-19, and asymptomatic individuals with suspected exposure were
233 preferentially tested in the US. Moreover, in contrast to our study, the US and
234 Canadian estimates were not adjusted for the sensitivity of RT-PCR assays and health
235 seeking behavior, and thus may be underestimated.

236

237 Our estimated hospitalization rate for a four-month COVID-19 outbreak was much
238 higher than that for a three-to-six-month COVID-19 outbreak in the US and Québec
239 (370 vs. 47-114 per 100,000 persons)^{27, 28, 29, 30}. We estimated that 76% of medically-
240 attended cases were hospitalized in Wuhan, while only 18% were hospitalized in the
241 US³⁰. The difference between these estimates could be explained by the potential
242 different clinical thresholds for hospitalization. We assumed that moderately ill cases
243 with radiographic evidence of pneumonia and more severe cases would be
244 hospitalized in the context of medical practices in China, based on the probability of
245 progression from disease to death³¹. However, such results may not apply to other
246 countries with different healthcare practice and general health seeking behaviors. For
247 example, Chinese patients are less likely to seek care at primary health institutions
248 than hospitals³².

249

250 The mortality rate of COVID-19 in Wuhan was lower than the excess mortality in
251 New York City (24,172 excess deaths³³ among 19,746,286 individuals, and thus 122
252 per 100,000 individuals), and Québec (52 per 100,000 persons)²⁸, but similar to the
253 national excess all-cause mortality in the US (122,300 excess deaths among
254 332,382,720 individuals, and thus 36.8 per 100,000 individuals)³⁴. In our study,
255 patients who died at home or died before being diagnosed were not considered, which
256 could have been important in the early phase of the epidemic due to under-
257 ascertainment. A recent comprehensive correction of official tallies of cases and
258 deaths by the Wuhan Authorities, included in this study, could minimize this under-
259 ascertainment. Further research should use excess mortality approaches³³ to capture
260 the full burden of the outbreak, when vital registration data for this period become
261 available.

262

263 Our estimates of sCFR (4.54% vs. 1.2-1.4%) and mCFR (7.40% vs 5.91%) for Wuhan
264 are higher than in prior modeling studies^{35, 36}. This is likely explained by the addition
265 of revised statistics on cases and deaths, and a more complete dataset with no right-
266 censored outcomes in our study. Large variations in mCFR were observed between
267 countries, which have not been systematically analyzed. Qualitatively, these
268 variations could be explained by differences in the sensitivity of surveillance systems

269 to detect cases at different levels of the severity pyramid, differences in clinical care
270 of severe and critical patients, and in age structure and underlying conditions of the
271 population.

272

273 Our HFR estimate (9.77%) is higher than the estimate obtained by Wang et al. in a
274 highly censored sample in Wuhan in the very early stages of the epidemic (4.3%)³⁷.

275 However, it is much lower than the 28% estimate obtained in two COVID-19-
276 designated hospitals for severe COVID-19 cases in Wuhan, probably due to the
277 particularly high proportion of severe and critical patients hospitalized in these
278 facilities (64% vs. 28%)³⁸. Our HFR estimate was lower than the 18.1% estimate in
279 France³⁹, probably due to aforementioned loose threshold for hospital admissions in
280 China and preference of seeking care in hospitals rather than outpatient settings.

281

282 We systematically compared the burden of the COVID-19 outbreak with that of the
283 1918 and 2009 influenza pandemics and seasonal influenza. Our COVID-19 estimates
284 are substantially higher than those of the 2009 influenza pandemic and seasonal
285 influenza, and similar to the 1918 influenza pandemic. However, the age pattern of
286 severe disease was clearly different. Our COVID-19 severity estimates increased with
287 age. In contrast, younger age groups were the most affected by 1918 and 2009
288 influenza pandemic, and both youngest and oldest individuals were the most affected
289 by seasonal influenza. Small changes were observed when we adjusted the overall

290 burden and clinical severity of seasonal and pandemic influenza using Wuhan age
291 profile as a reference (Supplementary Information File 5 and File 8). Comparison of
292 severity estimates between pandemics was difficult to standardize, particularly for
293 1918 influenza pandemic²³. The 1918 sCFR is based on data from a single US study
294 from more than a 100 years ago, at a time when awareness of viral diseases was
295 inexistent, case ascertainment and disease surveillance were limited, and definition of
296 clinical outcomes varied. Therefore, our comparison was not intended to quantify the
297 absolute value of differences, but to put the COVID-19 pandemic into perspective.

298

299 To put our results in perspective, it is important to stress that our COVID-19 estimates
300 refer to the first epidemic wave in Wuhan - a four-month long period. The epidemic
301 was controlled by intense interventions⁴. If the epidemic rebounds, as one would
302 expect if the infection was reintroduced in a population with low immunity, the
303 disease burden would rise. Moreover, given that the epidemic lasted only four months,
304 the stress on the healthcare system was tremendous, as severe cases and
305 hospitalizations were concentrated over a relatively short period of time. Furthermore,
306 neither seasonal nor pandemic influenza outbreaks were controlled, as vaccination
307 was either low or delayed until after the main wave had passed, and no social
308 distancing was put in place.

309

310 Using a simple data-driven approach, we quantitatively assessed the impact of
311 COVID-19 on the healthcare sector using the local number of ILI consultations and
312 SARI/pneumonia hospitalizations in the absence of COVID-19 as a reference. The
313 number of COVID-19 hospitalizations was several folds higher than that of baseline
314 SARI hospitalizations and 25-132 folds higher than that of pneumonia
315 hospitalizations among adults ≥ 20 years of age. This indicates that during this time
316 period, the Wuhan healthcare system considerably exceeded surge capacity,
317 highlighting the importance and necessity of preparedness for sufficient healthcare
318 resources. Moreover, there is a winter peak of consultations and hospitalizations
319 related to respiratory diseases such as seasonal influenza and respiratory syncytial
320 virus^{14, 40, 41}, which may have contributed to overwhelm the healthcare sector during
321 the first wave of the COVID-19 epidemic.

322

323 Our study has some limitations. Firstly, health seeking behavior maybe not constant
324 throughout the epidemic. In this survey, study participants in Wuhan were asked to
325 review their history of ARI between December 2019 and March 2020, and whether
326 they sought medical assistance for these symptoms¹³. However, since we did not
327 obtain the onset date of these symptoms, and hence we could not stratify health-
328 seeking behavior by COVID-19 epidemic phase. Instead, we calculated the overall
329 proportion of ARIs cases who sought medical care during the epidemic. If the
330 distribution of onset dates of ARIs cases in our sample was skewed towards the early

331 phase (late January) of the epidemic, the proportion seeking medical care may be
332 underestimated due to the overwhelmed health system. That would lead to an
333 overestimation of the number of symptomatic COVID-19 cases. Conversely, if the
334 distribution of onset dates was skewed towards the late phases of epidemic, we may
335 have underestimated the number of symptomatic COVID-19 cases. We conducted a
336 sensitivity analysis on the probability of seeking medical care, using the lower and
337 upper limits of the 95%CI of our survey. This analysis resulted in minor changes in
338 the disease burden and clinical severity estimates compared to the baseline analysis.

339

340 Secondly, missing or incorrect records of COVID-19 cases are inevitable during an
341 outbreak, particularly in the period when the healthcare capacity is overwhelmed. A
342 verification of reported COVID-19 cases was conducted by Wuhan Authorities to
343 correct for late reporting, omissions and mis-reporting, with 325 laboratory-confirmed
344 cases and 1,290 deaths added to official tallies. Due to the high specificity of RT-PCR
345 assay (almost 100%), false positives were rare^{42, 43, 44, 45}. We included in the analysis
346 clinically-diagnosed cases that were reported for a brief one-week period, when
347 testing could not keep up, so we inevitably overestimated the true number of COVID-
348 19 cases. Our sensitivity analyses showed that the exclusion of these clinically-
349 diagnosed cases led to decreased estimates of disease burden and increased estimates
350 of clinical severity. However, our conclusions are robust to these changes. Moreover,
351 while reporting of cases changed at the beginning of the pandemic as the definition of

352 COVID-19 suspected cases broadened to include a milder spectrum, we expect
353 reporting was relatively stable throughout the rest of the outbreak although this would
354 be difficult to prove conclusively.

355

356 Additionally, it is difficult to extrapolate our findings to other countries/regions since
357 estimates of clinical severity and disease burden of COVID-19 are influenced by
358 multiple factors such as the evolution of the epidemic, intervention policies, case
359 detection strategy, surge capacity of healthcare systems, differences in presentation,
360 triage, and treatment, and health seeking behavior over time and across locations. A
361 modelling study has revealed that containment has proved to be successful to control
362 the local COVID-19 epidemic in Wuhan. Without containment efforts, the number of
363 COVID-19 cases would have been an estimated 67-fold higher than that has been thus
364 far⁴⁶. Therefore, our estimates in Wuhan could represent the disease burden and
365 clinical severity in a region with 1) wide-spread community transmission of SARS-
366 CoV-2; 2) strict non-pharmaceutical interventions, referred as to “wartime measures”
367 in the study by Leung et al.⁴⁷; 3) extensive detection of all outpatients with fever¹⁰; 4)
368 enhanced healthcare capacity. Indeed, Wuhan experienced remarkably rapid and
369 extensive support from top-level medical staff drawn from all over China, as well as
370 rapid establishment of medical facilities like the Leishenshan and Fangcang shelter
371 hospitals^{48, 49, 50}. Although the COVID-19 pandemic has already spread across the
372 world, and the scale of epidemics in western countries, like the US and Brazil,

373 exceeded that in Wuhan by far, the pandemic in other countries is still ongoing and
374 any estimate is bound to be revised. Our estimates represent the full impact of a short
375 but intense first wave, and could be considered as benchmarks to plan intervention
376 strategies for a potential second wave of the pandemic.

377

378 In the first wave of the COVID-19 pandemic from December 2019 through March
379 2020 in Wuhan, China, intense community transmission caused higher disease burden
380 than the 2009 influenza pandemic and seasonal influenza. Overall, we find that the
381 clinical severity of COVID-19 seems to be in the same order of magnitude as that of
382 the 1918 influenza pandemic. In contrast to the age pattern of influenza virus
383 infection, however, the highest burden and clinical severity of COVID-19 is observed
384 among older adults, while children are less affected. During the epidemic of COVID-
385 19, the Wuhan healthcare system considerably exceeded surge capacity. This study is
386 helpful to guide intervention strategies and healthcare preparedness for the potential
387 re-emergence of COVID-19 in China and beyond.

388 **Figure legend**

389 **Figure 1. Severity levels of COVID-19 and schematic diagram of the baseline**
390 **analyses.**

391 A: Severity levels of infections with SARS-CoV-2 and parameters of interest. Each
392 level is assumed to be a subset of the level below. sCFR: symptomatic case-fatality
393 risk; sCHR: symptomatic case-hospitalization risk; mCFR: medically attended case-
394 fatality risk; mCHR: medically attended case-hospitalization risk; and HFR:
395 hospitalization-fatality risk.

396 B: Schematic diagram of the baseline analyses. Data source of COVID-19 cases in
397 Wuhan: *D1*) 32,583 laboratory-confirmed COVID-19 cases as of March 8⁴, *D2*)
398 17,365 clinically-diagnosed COVID-19 cases during February 9-19⁴, *D3*)daily
399 number of laboratory-confirmed cases on March 9-April 24³, *D4*) total number of
400 COVID-19 deaths as of April 24 obtained from the Hubei Health Commission³, *D5*)
401 325 laboratory-confirmed cases and *D6*) 1,290 deaths were added as of April 16
402 through a comprehensive and systematic verification by Wuhan Authorities³, and *D7*)
403 16,781 laboratory-confirmed cases identified through universal screening^{10, 11}. P_{se} :
404 RT-PCR sensitivity¹². $P_{med.care}$: proportion of seeking medical assistance among
405 patients suffering from acute respiratory infections¹³. (Red, blue and green arrows
406 separately denote the data flow from laboratory-confirmed cases of passive

407 surveillance, clinically-diagnosed cases, and laboratory-confirmed cases of active
408 screenings)

409

410 **Figure 2.** Rates of symptomatic cases and of medical consultation rates by age group
411 (mean, 95%CI)

412 a: rates of medical consultation associated with COVID-19 in Wuhan, China

413 b: rates of medical consultation associated with 2009 pandemic H1N1 influenza,

414 China¹⁴

415 c: rates of medical consultation associated with 2009 pandemic H1N1 influenza,

416 USA¹⁵

417 d: seasonal influenza-associated excess ILI outpatient consultations rates, China¹⁴

418 e: rates of medical consultation associated with seasonal influenza, USA¹⁵

419 **Figure 3.** Hospitalization rates

420 a: rates of hospitalization associated with COVID-19 in Wuhan, China (mean,

421 95%CI)

422 b: rates of hospitalization associated with 2009 pandemic H1N1 influenza, USA

423 (median, range)¹⁶

424 c: rates of hospitalization associated with seasonal influenza related SARI in

425 Jingzhou, Hubei province, China (median, range)¹⁷

426 d: rates of hospitalization associated with seasonal influenza, USA (mean, 95%CI)¹⁸.

427 ¹⁹

428 **Figure 4. Mortality rates**

429 a: rates of mortality associated with COVID-19 in Wuhan, China (mean, 95%CI)

430 b: rates of mortality associated with 2009 pandemic H1N1 influenza, USA (75%

431 percentile)²⁰

432 c: excess mortality rates associated with seasonal influenza, China (mean, 95%CI)²¹

433 d: excess mortality rates associated with seasonal influenza, USA (median, 95%

434 credibility interval)²²

435 **Figure 5.** Clinical severity

436 a: symptomatic case-fatality risk (sCFR) associated with COVID-19 in Wuhan, China

437 (mean, 95% CI)

438 b: symptomatic case-fatality risk (sCFR) associated with 1918 pandemic H1N1

439 influenza in August - December 1918, USA (mean)²³

440 c: symptomatic case-fatality risk (sCFR) associated with 2009 pandemic H1N1

441 influenza, USA (median,95% CI)²⁵

442 d: medically attended case-fatality risk (mCFR) associated with COVID-19 in Wuhan,

443 China (mean, 95% CI)

444 e: hospitalization-fatality risk (HFR) associated with COVID-19 in Wuhan, China

445 (mean, 95% CI)

446 f: hospitalization-fatality risk (HFR) associated with 2009 pandemic H1N1 influenza,

447 North America (mean,95% CI)²⁶

448 g: symptomatic case-hospitalization risk (sCHR) associated with COVID-19 in

449 Wuhan, China (mean, 95% CI)

450 h: symptomatic case-hospitalization risk (sCHR) associated with 2009 pandemic

451 H1N1 influenza, USA (median,95% CI)²⁵

452 i: medically attended case-hospitalization risk (mCHR) associated with COVID-19 in

453 Wuhan, China (mean, 95% CI)

454 **Methods**

455 **Case definitions**

456 Case definitions for laboratory-confirmed-cases were issued by the National Health
457 Commission of China, and included mild, moderate, severe, and critical cases. Cases
458 were confirmed by real-time reverse transcription polymerase chain reaction (RT-
459 PCR) or by viral sequencing indicating genomes highly homologous to SARS-CoV-
460 2^{5, 6, 7, 8}. Clinically-diagnosed cases included suspected cases with pneumonia as
461 indicated by chest radiography, but without virological confirmation of infection⁶.
462 The “clinical” definition was only used for one week in Hubei province as laboratory
463 testing capacity was insufficient, and led to a large number of clinical cases to be
464 isolated and treated without delay. These clinically-diagnosed cases were included in
465 our study, recognizing the value of a clinical definition at the peak of a pandemic and
466 in the context of limited laboratory testing capacity. The laboratory-confirmed cases
467 include mild-to-critical cases, while the clinically-diagnosed cases include moderate-
468 to-critical cases. Definitions are presented in detail in Supplementary information file
469 1.

470

471 **Data source**

472 *COVID-19 cases*

473 Our study aimed to account for underdiagnosis associated with the sensitivity of
474 laboratory assays, which is strongly dependent on the time lag between symptom

475 onset and diagnostic test¹². The distribution of lags varied at different phases of the
476 epidemic in Wuhan due to laboratory testing capacity⁴. Accordingly, the daily number
477 of COVID-19 cases by symptom onset date was preferred to the aggregated
478 cumulative data.

479

480 We obtained the following data: The daily number of laboratory-confirmed cases
481 based on date of symptom onset in Wuhan extracted from a study which included
482 32,583 laboratory-confirmed COVID-19 cases as of March 8 (*D1*), and 17,365
483 clinically-diagnosed COVID-19 cases during February 9-19 (*D2*)⁴. The daily number
484 of laboratory-confirmed cases in Wuhan based on reporting date on March 9-April 3
485 were extracted from the Hubei Health Commission (*D3*)³. The total number of
486 COVID-19 deaths in Wuhan as of April 24 was obtained from the Hubei Health
487 Commission (*D4*)³. To correct the late reporting, omissions and mis-reporting of
488 COVID-19 cases due to the healthcare capacity being overwhelmed during the
489 outbreak, Wuhan Authorities conducted a comprehensive and systematic verification
490 of reported COVID-19 cases between late March and middle April. A total of 325
491 laboratory-confirmed cases (*D5*) and 1,290 deaths (*D6*) were added on April 17³. The
492 number of COVID-19 cases stratified by age and clinical category was obtained from
493 the above sources *data D1* and *D2*, while the age profile of fatal cases was obtained
494 from the China CDC Weekly report^{4, 51}.

495

496 All of these datasets were registered through a surveillance system, which was
497 launched to record information on COVID-19 cases in China at the start of the
498 outbreak in late December 2019 in Wuhan⁹. These data were collected from passive
499 surveillance, and active door-to-door and individual-to-individual screenings for
500 fever. The active screening was implemented twice in Wuhan on a daily basis from
501 January 24-February 10, and February 17-19^{10, 11}. A total of 16,781 laboratory-
502 confirmed cases were identified through active screening (*D7*, Details shown in
503 Supplementary information file 2)^{10, 11}.

504

505 *Sensitivity of RT-PCR*

506 A study retrospectively analyzed the RT-PCR assays of 301 patients with 1,113
507 specimens in Wuhan, and found that RT-PCR sensitivity varied at different phases of
508 the epidemic due to the difference of interval between symptom onset and laboratory
509 testing (P_{se}) (Supplementary information file 9). The sensitivity of RT-PCR assays
510 was highest (97.9%) at an interval of <7 days¹².

511

512 *Health seeking behavior surveys*

513 A population-based telephone and online survey was conducted to understand the
514 health seeking behaviors of patients suffering from acute respiratory infections (i.e.,
515 fever with any symptoms of cough, and/or sore throat) during the epidemic of
516 COVID-19 in Wuhan. Of patients with acute respiratory infections, 35.4% (95% CI

517 28.4%-43.9%) sought medical care, by adjusting for the age structure of Wuhan
518 population. Children had a higher probability of medical attendance than adults
519 ($P_{med.care}$)¹³.

520

521 *Other datasets*

522 A total of 10.7 million persons lived in Wuhan during the epidemic⁵². The age profile
523 of the Wuhan population was obtained from the China Statistic Yearbook⁵³. To
524 compare the burden of COVID-19 to baseline activity of acute respiratory infections,
525 we obtained reference historical data on ILI surveillance in Hubei province and SARI
526 surveillance in Jingzhou city, Hubei province^{14, 17, 21}. Additionally, we collected the
527 annual number of consultations in pediatric and internal medicine departments in
528 Hubei, and the national number of pneumonia hospitalization rates from the Chinese
529 Health Statistics Yearbook⁵⁴. All these data were collected from publicly available
530 sources and did not contain any personal identifiable information. Summary of data
531 were presented in Supplementary information file 10.

532

533 **Statistical analysis**

534 Fig. 1 described the metrics we estimated, data flow, data analysis procedure and
535 assumptions in the baseline analyses. All analyses were performed in R version
536 3.6.3⁵⁵.

537

538 *Reported COVID-19 cases in Wuhan*

539 In the baseline analysis, we considered COVID-19 cases in Wuhan as those with
540 laboratory-confirmation or with a clinical diagnosis (for the brief period where the
541 clinical definition was in place) and tabulated data by symptom onset date. The
542 interval between symptom onset and diagnosis was obtained from data $D1$ ⁴. Then, we
543 randomly simulated 10,000 draws from a gamma distribution representing these time
544 intervals to estimate onset dates for laboratory-confirmed cases reported between
545 March 9-April 3 (*data D3*), and added laboratory-confirmed cases (*data D5*). This
546 allowed us to impute onset dates for cases that did not have this information.

547

548 *Medical consultations*

549 All cases from passive surveillance were considered as medical attendance (data
550 $D1+D3+D5$, and $D2$). In the baseline analysis, we assumed that a proportion of mild
551 cases, and all moderate-to-critical cases captured by active screenings in the
552 community (data $D7$) would eventually seek medical care given that the health system
553 was not overwhelmed (*Assumption 1*). The health seeking behavior of mild cases was
554 assumed to be the same as aforementioned patients with acute respiratory infections
555 during the COVID-19 epidemic ($P_{med.care}$)¹³. Hence, to estimate medically attended
556 cases, we only excluded a proportion of $(1-P_{med.care})$ mild cases identified by
557 community screening from the total reported COVID-19 cases. Moreover, the number

558 of laboratory-confirmed cases from official reports (data $D1+D3+D5$, and $D7$) was
559 divided by the sensitivity of RT-PCR (P_{se}) to account for underdiagnoses.

560

561 *Symptomatic cases*

562 In the baseline analysis, we assumed the cases from surveillance system (data
563 $D1+D3+D5$, and $D2$) had the same health seeking behavior as those captured by
564 active screenings in the community (data $D7$) given that the health system was not
565 overwhelmed (*Assumption 1*). Accordingly, the number of mild symptomatic cases
566 was estimated by dividing reported mild COVID-19 cases by the probability of
567 seeking medical care, conditionally on self-reported acute respiratory infection¹³.

568 Adjustment of sensitivity of RT-PCR was considered as well.

569

570 *Hospitalized cases*

571 Moderate-to-critical COVID-19 cases had radiographic evidence of pneumonia, while
572 mild cases were defined as those without radiographic evidence of pneumonia^{5, 6, 7, 8}.

573 Chest x-ray confirmed pneumonia is a threshold for hospital admissions in China.

574 Accordingly, in our study, estimates for SARS-CoV-2 related hospitalizations
575 excluded patients defined as mild cases in the baseline analysis. (*Assumption 2*)

576

577 In above analyses, to account for the uncertainty of two parameters (RT-PCR
578 sensitivity and probability of seeking medical care), we conducted a Monte Carlo

579 Simulation by drawing 10,000 samples on the basis of Binomial distributions. We
580 generated 10,000 estimates for the number of COVID-19 cases, based on which we
581 calculated the median, and 95% CIs (the 2.5th and 97.5th percentiles) for the
582 outcomes of interest in this study.

583

584 Additionally, below sensitivity analyses were conducted: in scenario i) for above
585 *Assumptions 1) and 2)*, we assumed moderate cases had the same health seeking
586 behavior as mild cases, i.e., only a proportion of moderate cases sought medical
587 assistance ($P_{med.care}$); and in scenario ii) we excluded clinically-diagnosed cases. Chi-
588 square tests were used to compare the estimates of baseline and sensitivity analyses.
589 Two-sided P values <0.05 were considered to indicate statistical significance.

590

591 *Disease burden*

592 We used the number of ILI consultations, and the number of SARI/pneumonia
593 hospitalizations in the absence of COVID-19 outbreak as a reference to estimate
594 COVID-19 related ILI medical consultations, and COVID-19 associated
595 SARI/pneumonia hospitalization rate. Estimation of the number of ILI cases and
596 SARI/pneumonia hospitalizations during the periods are shown in Supplementary
597 Information file 11-14.

598

599 Moreover, for comparison with historical outbreaks, we conducted a narrative review
600 on estimates of disease burden and clinical severity for the 1918 and 2009 influenza
601 pandemics, as well as seasonal influenza in China and USA (Summary of studies
602 shown in Supplementary Information file 4-5). The age profile of COVID-19 cases
603 was obtained from *data DI*⁴, in which COVID-19 cases were broken down into 20-
604 year age categories. We could not generate disease burden and clinical severity
605 estimates for influenza using the same age stratification because numerators and
606 denominators were not available from the literatures.

607

608 **Role of the funding source**

609 The funder of the study had no role in study design, data collection, data analysis, data
610 interpretation, or writing of the report. The corresponding author had full access to all
611 the data in the study and had final responsibility for the decision to submit for
612 publication.

613 **References**

- 614 1. Johns Hopkins University. Coronavirus (COVID-19) Information and Updates.
615 <https://www.coronavirustraining.org/live-map> (accessed July 26 2020).
- 616 2. Centers for Disease Control and Prevention. Past Pandemics.
617 <https://www.cdc.gov/flu/pandemic-resources/basics/past-pandemics.html> (accessed
618 May 4 2020).
- 619 3. Health Commission of Hubei Province. Daily report on epidemic situation of COVID-19
620 in Hubei province. (In Chinese).
621 <http://wjw.hubei.gov.cn/bmdt/ztzl/fkxxgzbdgrfyyq/xxfb/index.shtml> (accessed July 22
622 2020).
- 623 4. Pan A., *et al.* Association of Public Health Interventions With the Epidemiology of the
624 COVID-19 Outbreak in Wuhan, China. *JAMA* **323**, 1915-1923 (2020).
- 625 5. Zhang J., *et al.* Evolving epidemiology and transmission dynamics of novel coronavirus
626 disease 2019 outside Hubei Province in China: a descriptive and modeling study. *Lancet*
627 *Infect. Dis.* **20**, 793-802 (2020).
- 628 6. National Health Commission of China. The diagnosis and treatment scheme of novel
629 coronavirus diseases 2019 (Trial version 5th).
630 http://www.gov.cn/zhengce/zhengceku/2020-02/05/content_5474791.htm (accessed
631 February 25 2020).
- 632 7. National Health Commission of China. The diagnosis and treatment scheme of novel
633 coronavirus diseases 2019 (Trial version 6th).
634 http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm (accessed
635 February 25 2020).
- 636 8. National Health Commission of China. The diagnosis and treatment scheme of novel
637 coronavirus diseases 2019 (Trial version 7th).
638 http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm (accessed
639 February 25 2020).
- 640 9. Chinese Center for Disease Control and Prevention. Epidemic update and risk
641 assessment of 2019 Novel Coronavirus. 2020. (In Chinese).
642 <http://www.chinacdc.cn/yrdgz/202001/P020200128523354919292.pdf> (accessed
643 January 31 2020).
- 644 10. The State Council of the People's Republic of China. Announcement of Wuhan
645 Headquarters for the Control and Treatment of Novel Pneumonia (No. 7) (In Chinese)
646 http://www.gov.cn/xinwen/2020-01/24/content_5472017.htm (accessed January 24
647 2020).
- 648 11. China Central Television. Report on results of 3-day screening in each district of Wuhan.
649 (In Chinese).
650 <http://news.cctv.com/2020/02/20/ARTIfdQ2kV0eRTE4rgX2Aa3D200220.shtml> (accessed
651 February 20 2020).
- 652 12. Xiao A., Tong Y., Gao C., Zhu L., Zhang Y., Zhang S. Dynamic Profile of RT-PCR Findings
653 from 301 COVID-19 Patients in Wuhan, China: A Descriptive Study. *J. Clin. Virol.*, 104346

- 654 (2020).
- 655 13. Yang J., *et al.* Health seeking behaviors of patients with acute respiratory infections
656 during the outbreak of novel coronavirus disease 2019 in Wuhan, China. *medRxiv*,
657 <https://doi.org/10.1101/2020.1105.1105.20091553> (2020).
- 658 14. Feng L., *et al.* Burden of influenza-associated outpatient influenza-like illness
659 consultations in China, 2006-2015: A population-based study. *Influenza Other Respir.*
660 *Viruses* **14**, 162-172 (2020).
- 661 15. Fowlkes A., *et al.* Incidence of medically attended influenza during pandemic and post-
662 pandemic seasons through the Influenza Incidence Surveillance Project, 2009-13. *Lancet*
663 *Respir. Med.* **3**, 709-718 (2015).
- 664 16. Shrestha S. S., *et al.* Estimating the burden of 2009 pandemic influenza A (H1N1) in the
665 United States (April 2009-April 2010). *Clin. Infect. Dis.* **52 Suppl 1**, S75-82 (2011).
- 666 17. Yu H., *et al.* The substantial hospitalization burden of influenza in central China:
667 surveillance for severe, acute respiratory infection, and influenza viruses, 2010-2012.
668 *Influenza Other Respir. Viruses* **8**, 53-65 (2014).
- 669 18. Palekar R. S., *et al.* Burden of influenza-associated respiratory hospitalizations in the
670 Americas, 2010-2015. *PloS One* **14**, e0221479 (2019).
- 671 19. Reed C., *et al.* Estimating influenza disease burden from population-based surveillance
672 data in the United States. *PloS One* **10**, e0118369 (2015).
- 673 20. Dawood F. S., *et al.* Estimated global mortality associated with the first 12 months of
674 2009 pandemic influenza A H1N1 virus circulation: a modelling study. *Lancet Infect. Dis.*
675 **12**, 687-695 (2012).
- 676 21. Li L., *et al.* Influenza-associated excess respiratory mortality in China, 2010-15: a
677 population-based study. *Lancet Public Health* **4**, e473-e481 (2019).
- 678 22. Iuliano A. D., *et al.* Estimates of global seasonal influenza-associated respiratory
679 mortality: a modelling study. *Lancet.* **391**, 1285-1300 (2018).
- 680 23. Frost W. H. The Epidemiology of Influenza. *Public Health Rep.* **34**, 1823-1836 (1919).
- 681 24. Mamelund S. E., Haneberg B., Mjaaland S. A Missed Summer Wave of the 1918-1919
682 Influenza Pandemic: Evidence From Household Surveys in the United States and
683 Norway. *Open Forum Infect. Dis.* **3**, ofw040 (2016).
- 684 25. Presanis A. M., *et al.* The severity of pandemic H1N1 influenza in the United States, from
685 April to July 2009: a Bayesian analysis. *PLoS Med.* **6**, e1000207 (2009).
- 686 26. Wong J. Y., *et al.* Hospitalization Fatality Risk of Influenza A(H1N1)pdm09: A Systematic
687 Review and Meta-Analysis. *Am. J. Epidemiol.* **182**, 294-301 (2015).
- 688 27. Stokes E. K., *et al.* Coronavirus Disease 2019 Case Surveillance - United States, January
689 22-May 30, 2020. *MMWR* **69**, 759-765 (2020).
- 690 28. Bignami S., Assche A. V. Assessing the burden of COVID-19 in Canada. *medRxiv*,
691 <https://doi.org/10.1101/2020.1106.1114.20130815> (2020).
- 692 29. Garg S., *et al.* Hospitalization Rates and Characteristics of Patients Hospitalized with
693 Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30,
694 2020. *MMWR* **69**, 458–464 (2020).
- 695 30. Lewnard J. A., *et al.* Incidence, clinical outcomes, and transmission dynamics of

- 696 hospitalized 2019 coronavirus disease among 9,596,321 individuals residing in California
697 and Washington, United States: a prospective cohort study. *BMJ* **369**, m1923 (2020).
- 698 31. WHO-China Joint Mission. Report of the WHO-China Joint Mission on Coronavirus
699 Disease 2019 (COVID-19). [https://www.chinadaily.com.cn/pdf/2020/who-china-joint-](https://www.chinadaily.com.cn/pdf/2020/who-china-joint-mission-on-covid-19-final-report.pdf)
700 [mission-on-covid-19-final-report.pdf](https://www.chinadaily.com.cn/pdf/2020/who-china-joint-mission-on-covid-19-final-report.pdf) (accessed March 19 2020).
- 701 32. Zheng L. Analysis and suggestion on the factors leading to the difficulty in the
702 construction of hierarchical diagnosis system. (In Chinese). *Chinese Health Econ* **38**, 12-
703 15 (2019).
- 704 33. New York City Department of Health and Mental Hygiene (DOHMH) COVID-19
705 Response Team. Preliminary Estimate of Excess Mortality During the COVID-19
706 Outbreak — New York City, March 11–May 2, 2020. *MMWR* **69**, 603–605 (2020).
- 707 34. Weinberger D. M., *et al.* Estimation of Excess Deaths Associated With the COVID-19
708 Pandemic in the United States, March to May 2020. *JAMA Intern. Med.*, doi:
709 10.1001/jamainternmed.2020.3391 (2020).
- 710 35. Wu J. T., *et al.* Estimating clinical severity of COVID-19 from the transmission dynamics
711 in Wuhan, China. *Nat. Med.* **26**, 506–510 (2020).
- 712 36. Tian H., *et al.* An investigation of transmission control measures during the first 50 days
713 of the COVID-19 epidemic in China. *Science* **368**, 638–642 (2020).
- 714 37. Wang D., *et al.* Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel
715 Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* **323**, 1061–1069 (2020).
- 716 38. Zhou F., *et al.* Clinical course and risk factors for mortality of adult inpatients with
717 COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* **395**, 1054–1062
718 (2020).
- 719 39. Henrik S., *et al.* Estimating the burden of SARS-CoV-2 in France. *Science* **369**, 208–211
720 (2020).
- 721 40. Yu J., *et al.* Respiratory Syncytial Virus Seasonality, Beijing, China, 2007–2015. *Emerg.*
722 *Infect. Dis.* **25**, 1127–1135 (2019).
- 723 41. Zhang Z., *et al.* Genetic variability of respiratory syncytial viruses (RSV) prevalent in
724 Southwestern China from 2006 to 2009: emergence of subgroup B and A RSV as
725 dominant strains. *J. Clin. Microbiol.* **48**, 1201–1207 (2010).
- 726 42. Sheikhzadeh E., Eissa S., Ismail A., Zourob M. Diagnostic techniques for COVID-19 and
727 new developments. *Talanta* **220**, 121392 (2020).
- 728 43. Corman V. M., *et al.* Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-
729 PCR. *Euro. Surveill.* **25**, (2020).
- 730 44. He J., *et al.* Diagnostic performance between CT and initial real-time RT-PCR for
731 clinically suspected 2019 coronavirus disease (COVID-19) patients outside Wuhan,
732 China. *Respir. Med.* **168**, 105980 (2020).
- 733 45. Bordi L., *et al.* Rapid and sensitive detection of SARS-CoV-2 RNA using the Simplexa™
734 COVID-19 direct assay. *J. Clin. Virol.* **128**, 104416 (2020).
- 735 46. Lai S., *et al.* Effect of non-pharmaceutical interventions to contain COVID-19 in China.
736 *Nature*, doi: 10.1038/s41586-41020-42293-x (2020).
- 737 47. Leung K., Wu J. T., Liu D., Leung G. M. First-wave COVID-19 transmissibility and severity

- 738 in China outside Hubei after control measures, and second-wave scenario planning: a
739 modelling impact assessment. *Lancet*. **395**, 1382-1393 (2020).
- 740 48. Chen S., *et al.* Fangcang shelter hospitals: a novel concept for responding to public
741 health emergencies. *Lancet*. **395**, 1305-1314 (2020).
- 742 49. The State Council of the People's Republic of China. Press Conference of the Joint
743 Prevention and Control Mechanism of the State Council. (In Chinese).
744 <http://www.gov.cn/xinwen/gwylflkjz48/index.htm> (accessed March 8 2020).
- 745 50. Li Z., *et al.* Active case finding with case management: the key to tackling the COVID-19
746 pandemic. *Lancet*. **396**, 63-70 (2020).
- 747 51. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The
748 Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases
749 (COVID-19) — China, 2020. *China CDC Weekly* **2**, 113-122 (2020).
- 750 52. Health Commission of Hubei Province. The 20th press conference on prevention and
751 control of pneumonia caused by novel coronavirus. (In Chinese).
752 http://wjw.hubei.gov.cn/fbjd/dtyw/202002/t20200211_2023793.shtml (accessed
753 February 11 2020).
- 754 53. National Bureau of Statistics. China Statistic Yearbook. <http://www.stats.gov.cn/tjsj/ndsj/>
755 (accessed March 3 2020).
- 756 54. China Health Commission. Chinese Health Statistical Yearbook. China Peking Union
757 Medical College Press. (In Chinese).
758 <http://navi.cnki.net/KNavi/YearbookDetail?pcode=CYFD&pykm=YSIFE&bh=> (accessed
759 March 11 2020).
- 760 55. The R Project for Statistical Computing. <https://www.r-project.org/> (accessed March 18
761 2020).
- 762

763 **Acknowledgments**

764 The study was supported by grants from the National Science Fund for Distinguished
765 Young Scholars (No. 81525023), National Science and Technology Major Project of
766 China (No. 2018ZX10201001-010, No. 2018ZX10713001-007, No.
767 2017ZX10103009-005).

768

769 **Author Contributions**

770 H.Y. conceived, designed and supervised the study. J.Y., X.C., X.D., Z.C., H.G.,
771 H.Y., Q.W., H.S. and S.L. participated in data collection. J.Y., X.C., X.D., Z.C., and
772 H.G. analyzed the data, and prepared the tables and figures. J.Y. prepared the first
773 draft of the manuscript. S.L., M.A., C.V. and H.Y. commented on the data and its
774 interpretation, revised the content critically. All authors contributed to review and
775 revision and approved the final manuscript as submitted and agree to be accountable
776 for all aspects of the work.

777

778 **Declaration of interests**

779 H.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang
780 HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical

781 Company. None of those research funding is related to COVID-19. All other authors
782 report no competing interests.


783

784 **Additional information**


785 **Supplementary Information** is available for this paper.

786 **Correspondence and requests for materials** should be addressed to J.Y., and H.Y.

a









b




Assumptions:


- 1) In the baseline analysis, it was assumed that a proportion of mild cases, and all moderate-to-critical cases captured by universal screenings in the community would eventually seek medical care given that the health system was not overwhelmed. And it was assumed that the cases from surveillance system had the same health seeking behavior as them;
- 2) In the baseline analysis, all moderate/severe/critical COVID-19 cases require hospitalization, while mild cases do not.

a Wuhan, China**b China****c USA****d China****e USA**


a Wuhan, China




b USA



c Jingzhou, China




d USA




■ COVID-19
 ■ 2009 pandemic H1N1 influenza
 ■ Seasonal influenza


a Wuhan, China




b USA












c China



d USA



COVID-19 2009 pandemic H1N1 influenza Seasonal influenza



● COVID-19

● 1918 pandemic H1N1 influenza

● 2009 pandemic H1N1 influenza